Healthcare
Bio-Techne Corporation(TECH)
Live Price
Offline$57.94
+5.35% today
Window Change
+12.11%
Window
May 29, 2026 โ Jun 18, 2026
- Market Cap
- $8.61B
- Revenue Growth
- +5.2%
- EPS Growth
- -56.1%
- Dividend Yield
- 0.6%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Bio-Techne Corporation (TECH) is a Healthcare stock with a market cap of $8.61B and listed on NASDAQ. The stock last traded around $57.94 and up 12.1% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of +5.2%, EPS growth of -56.1%, a dividend yield of 0.6%. What stands out right now is revenue +5.2%, EPS -56.1%, free cash flow +8.7% with operating margin 9.6% and ROIC 3.5%. The dividend is present but secondary, with a yield around 0.6%. Valuation already assumes a fairly strong business story at P/E 105.7 and price/sales 7.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TECH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+5.2% vs +7.6% peer median
Operating Margin
Below sector median
+9.6% vs +19.4% peer median
P/E
Above sector median
105.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 6, 2026 with an EPS surprise of -3.6% and a revenue surprise of -1.5%.
The operating picture looks softer than before
Revenue is at +5.2% and EPS is at -56.1%, with operating margin around 9.6%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 5, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TECH
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TECH Max Drawdown
-3.70%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TECH and SPY.
Company Overview
Bio-Techne Corporation
NASDAQ Global Select
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
- Leadership
- Kim Kelderman
- IPO Date
- Feb 9, 1989
- Employees
- 3.1k
- Street Address
- 614 McKinley Place N.E.
- Mailing
- Minneapolis, MN, 55413
- Region
- Minneapolis, MN, US
- Reporting Currency
- USD
- Investor Line
- 612 379 8854
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 105.7
- EV/EBITDA
- 38.7
- Price/Sales
- 7.1
- Price/Book
- 4.3
Growth
- Revenue
- +5.2%
- EPS
- -56.1%
- Free Cash Flow
- +8.7%
Profitability
- Gross Margin
- 65.2%
- Operating Margin
- 9.6%
- Net Margin
- 6.7%
- ROE
- 4.1%
- ROIC
- 3.5%
Balance Sheet
- Debt/Equity
- 0.17
- Current Ratio
- 4.54
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.